$465.23
4.811.04%
Last update: Nov 10, 3:36 AM
Amgen Inc
AMGNNASDAQ
Amgen rose 43.7% from $323.66 to $465.23, ahead of the S&P 500's +10.5%. Its worst day was Sep 8 (−10.1%), and its low came Dec 9 at $313.85.
Nov 10, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Amgen closed at its lowest level of the year, 3.0% below where the year started.
−2.3% · S&P 500 −0.1%
EPS of $5.29 beat the $4.75 estimate on $9.9B revenue (est. $9.5B); FY revenue guidance of $37.0B–$38.4B against the $37.0B consensus.
Story events cover the past 12 months · Times ET
+8.2%, the year's best day · S&P 500 −0.5%
EPS of $5.15 beat the $4.76 estimate on $8.6B revenue (est. $8.6B); FY revenue guidance of $37.1B–$38.5B against the $37.8B consensus.
−4.7% · S&P 500 +0.3%
Amgen shares rose 4.8%, while the S&P 500 rose 1.7%.
+4.8% · S&P 500 +1.7%
EPS of $6.29 beat the $5.60 estimate on $10.1B revenue (est. $9.4B); FY revenue guidance of $38.2B–$39.4B against the $37.8B consensus.
+4.6% · S&P 500 −0.2%
Amgen sank 9.8% Tuesday after Novartis’ pelacarsen missed its Phase 3 endpoint, casting doubt on rival Lp(a) drug olpasiran.
−10.1%, the year's worst day · S&P 500 −0.5%
EPS of $6.45 beat the $5.77 estimate on $10.4B revenue (est. $10.0B); FY revenue guidance of $38.9B–$39.7B against the $39.0B consensus.
+3.7% · S&P 500 +1.7%
Where it ended: a close of $465.23 on Nov 9, 2026. Up next: Q4 2026 earnings on Feb 2, 2027 (EPS est. $5.62, revenue est. $10.4B).
As of the Nov 9, 2026 close
Replay the year: the line draws itself and stops at each of the 7 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for AMGN and SPY from Benzinga historical bars. Not investment advice.
